Clinical Trial Update: Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 randomized, double-masked trial of QPI-1007 in acute nonarteritic anterior ischemic optic neuropathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonarteritic Anterior Ischemic Optic Neuropathy

Drugs mentioned

• QPI-1007 (p53-targeted siRNA)

Snippet

Sponsor: Quark Pharmaceuticals | Conditions: Non Arteritic Anterior Ischemic Optic Neuropathy | Phase 2, Phase 3 | Status: TERMINATED